Companies: 10,795·Total market cap: $144.5T
NLS Pharmaceutics AG

NLS Pharmaceutics AG

NLSPNASDAQHealthcare
$2.91
$-0.42(-12.61%)
Market Cap$919601
P/E Ratio—
52W High$43.4
52W Low$0.76
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

NLS Pharmaceutics AG (NLSP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001783036 · NLSP · NASDAQ · as of Jun 9, 2026

Filing snapshot

383
Total Filings
6-K
Latest Form
2026-06-05
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001783036 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-04-29
Fiscal Year End
Apr 29, 2026
Accession No.
0001213900-26-049307
Primary Document
ea0287509-20f_newcelx.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001783036 · Accession 0001213900-26-049307

Latest Key Filings

6-KQuarterly Report
CURRENT REPORT
2026-06-05
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
CURRENT REPORT
2026-06-05
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-05-27
View
EFFECTEFFECT
EFFECT
2026-05-15
View
DD
D
2026-05-13
View
F-3F-3
REGISTRATION STATEMENT
2026-05-11
View
EFFECTEFFECT
EFFECT
2026-05-06
View
POS AMPOS AM
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1
2026-05-05
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-05-04
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-04-30
View
20-FAnnual Report (Foreign Issuer)
ANNUAL REPORT
2026-04-29
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-04-20
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-04-01
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-18
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-18
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-18
View
Showing 1–15 of 381 filingsForm 4 / 144 hidden· 383 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001783036  |  Exchange: NASDAQ · Healthcare

NLS Pharmaceutics AG (NASDAQ: NLSP) has submitted 383 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001783036, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is NLS Pharmaceutics AG's most comprehensive regulatory disclosure. The most recent NLS Pharmaceutics AG 10-K was filed on 2026-04-29 for fiscal year ending 2026. Historical NLSP 10-K annual reports are available from 2019 through 2026.

Investors researching NLS Pharmaceutics AG SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
PRE SEC Filings →SRZN SEC Filings →SABS SEC Filings →CELU SEC Filings →KTTA SEC Filings →BACK SEC Filings →NUWE SEC Filings →OCEA SEC Filings →
→ NLSP Financials→ NLSP Earnings→ NLSP Insider Trades

Frequently Asked Questions

NLSP SEC Filings · 8 questions

NLS Pharmaceutics AG (NLSP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 383 filings and access original documents at no cost. NLS Pharmaceutics AG's CIK is 0001783036.

NLSP SEC filingsNLS Pharmaceutics AG SEC documentsfind NLSP 10-K